Skip to main content
Top
Published in: BMC Health Services Research 1/2017

Open Access 01-12-2017 | Research article

Adherence to treatment guidelines: the association between stroke risk stratified comparing CHADS2 and CHA2DS2-VASc score levels and warfarin prescription for adult patients with atrial fibrillation

Authors: Scott A. Chapman, Catherine A. St Hill, Meg M. Little, Michael T. Swanoski, Shellina R. Scheiner, Kenric B. Ware, M. Nawal Lutfiyya

Published in: BMC Health Services Research | Issue 1/2017

Login to get access

Abstract

Background

Ischemic stroke is a risk associated with atrial fibrillation (AF) and is estimated to occur five times more often in afflicted patients than in those without AF. Anti-thrombotic therapy is recommended for the prevention of ischemic stroke. Risk stratification tools, such as the CHADS2, and more recently the CHA2DS2-VASc, for predicting stroke in patients with AF have been developed to determine the level of stroke risk and assist clinicians in the selection of antithrombotic therapy. Warfarin, for stroke prevention in AF, is the most commonly prescribed anticoagulant in North America. The purpose of this study was to examine the utility of using the CHADS2 score levels (low and high) in contrast to the CHA2DS2-VASc when examining the outcome of warfarin prescriptions for adult patients with AF. The CHA2DS2-VASc tool was not widely used in 2010, when the data analyzed were collected. It has only been since 2014 that CHA2DS2-VASc criteria has been recommended to guide anticoagulant treatment in updated AF treatment guidelines.

Methods

Bivariate and multivariate data analysis strategies were used to analyze 2010 National Ambulatory Care Survey (NAMCS) data. NAMCS is designed to collect data on the use and provision of ambulatory care services nationwide. The study population for this research was US adults with a diagnosis of AF. Warfarin prescription was the dependent variable for this study. The study population was 7,669,844 AF patients.

Results

Bivariate analysis revealed that of those AF patients with a high CHADS2 score, 25.1% had received a warfarin prescription and 18.8 for those with a high CHA2DS2-VASc score. Logistic regression analysis yielded that patients with AF had higher odds of having a warfarin prescription if they had a high CHADS2 score, were Caucasian, lived in a zip code where < 20% of the population had a university education, and lived in a zip code where < 10% of the population were living in households with incomes below the federal poverty level. Further, the analysis yielded that patients with AF had lesser odds of having a warfarin prescription if they were ≥ 65 years of age, female, or had health insurance.

Conclusions

Overall, warfarin appears to be under-prescribed for patients with AF regardless of the risk stratification system used. Based on the key findings of our study opportunities for interventions are present to improve guideline adherence in alignment with risk stratification for stroke prevention. Interprofessional health care teams can provide improved medical management of stroke prevention for patients with AF. These interprofessional health care teams should be constituted of primary care providers (physicians, physician assistants, and nurse practitioners), nurses (RN, LPN), and pharmacists (PharmD, RPh).
Literature
2.
go back to reference Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142–7.CrossRefPubMed Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142–7.CrossRefPubMed
3.
go back to reference Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–5.CrossRefPubMed Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–5.CrossRefPubMed
4.
go back to reference Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.CrossRefPubMed Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.CrossRefPubMed
5.
6.
go back to reference No author. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–57. No author. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–57.
7.
go back to reference Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27:1760–4.CrossRefPubMed Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27:1760–4.CrossRefPubMed
8.
go back to reference Brown DL, Boden-Albala B, Langa KM, Lisabeth LD, Fair M, Smith MA, et al. Projected costs of ischemic stroke in the United States. Neurology. 2006;67:1390–5.CrossRefPubMed Brown DL, Boden-Albala B, Langa KM, Lisabeth LD, Fair M, Smith MA, et al. Projected costs of ischemic stroke in the United States. Neurology. 2006;67:1390–5.CrossRefPubMed
9.
go back to reference Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9:348–56.CrossRefPubMed Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9:348–56.CrossRefPubMed
10.
go back to reference Casciano JP, Singer DE, Kwong WJ, Fox ES, Martin BC. Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use. Am J Cardiovasc Drugs. 2012;12:313–23.CrossRefPubMed Casciano JP, Singer DE, Kwong WJ, Fox ES, Martin BC. Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use. Am J Cardiovasc Drugs. 2012;12:313–23.CrossRefPubMed
11.
go back to reference Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.CrossRefPubMed Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.CrossRefPubMed
12.
go back to reference Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: do we anticoagulate CHADS2 or CHA2DS2-VASc >1, or higher? Thromb Haemost. 2015;113:1165–9.CrossRefPubMed Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: do we anticoagulate CHADS2 or CHA2DS2-VASc >1, or higher? Thromb Haemost. 2015;113:1165–9.CrossRefPubMed
13.
go back to reference Mohammed MA, Marshall T, Nirantharakumar K, Stevens A, Fitzmaurice D. Patterns of warfarin use in subgroups of patients with atrial fibrillation: a cross-sectional analysis of 430 general practices in the United Kingdom. PLoS One. 2013;8:e61979.CrossRefPubMedPubMedCentral Mohammed MA, Marshall T, Nirantharakumar K, Stevens A, Fitzmaurice D. Patterns of warfarin use in subgroups of patients with atrial fibrillation: a cross-sectional analysis of 430 general practices in the United Kingdom. PLoS One. 2013;8:e61979.CrossRefPubMedPubMedCentral
14.
go back to reference Rosanio S, Keylani AM, D’Agostino DC, DeLaughter CM, Vitarelli A. Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. Int J Cardiol. 2014;174:471–83.CrossRefPubMed Rosanio S, Keylani AM, D’Agostino DC, DeLaughter CM, Vitarelli A. Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. Int J Cardiol. 2014;174:471–83.CrossRefPubMed
15.
go back to reference Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–106.CrossRefPubMed Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–106.CrossRefPubMed
16.
go back to reference Hart RG. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.CrossRefPubMed Hart RG. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.CrossRefPubMed
17.
go back to reference Odum LE, Cochran KA, Aistrope DS, Snella KA. The CHADS2 versus the new CHA2DS2-VASc scoring systems for guiding antithrombotic treatment of patients with atrial fibrillation: review of the literature and recommendations for use. Pharmacotherapy. 2012;32:285–96.CrossRefPubMed Odum LE, Cochran KA, Aistrope DS, Snella KA. The CHADS2 versus the new CHA2DS2-VASc scoring systems for guiding antithrombotic treatment of patients with atrial fibrillation: review of the literature and recommendations for use. Pharmacotherapy. 2012;32:285–96.CrossRefPubMed
18.
go back to reference Shroff G, Solid C, Herzog C. Atrial fibrillation, stroke, and anticoagulation in medicare beneficiaries: trends by age, sex, and race, 1992–2010. J Am Heart Assoc. 2014;3:e000756.CrossRefPubMedPubMedCentral Shroff G, Solid C, Herzog C. Atrial fibrillation, stroke, and anticoagulation in medicare beneficiaries: trends by age, sex, and race, 1992–2010. J Am Heart Assoc. 2014;3:e000756.CrossRefPubMedPubMedCentral
19.
go back to reference Raji M, Lowery M, Lin Y, Kuo Y, Baillargeon J, Goodwin J. National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries. Ann Pharmacother. 2013;47:35–42.CrossRefPubMedPubMedCentral Raji M, Lowery M, Lin Y, Kuo Y, Baillargeon J, Goodwin J. National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries. Ann Pharmacother. 2013;47:35–42.CrossRefPubMedPubMedCentral
20.
go back to reference Rowan S, Bailey D, Bublitz C, Anderson R. Trends in anticoagulation for atrial fibrillation in the U.S.: an analysis of the national ambulatory medical care survey database. J Am Coll Cardiol. 2007;49:1561–5.CrossRefPubMed Rowan S, Bailey D, Bublitz C, Anderson R. Trends in anticoagulation for atrial fibrillation in the U.S.: an analysis of the national ambulatory medical care survey database. J Am Coll Cardiol. 2007;49:1561–5.CrossRefPubMed
21.
go back to reference Niska R, Han B. Anticoagulation for patients with atrial fibrillation in ambulatory care settings. J Am Board Fam Med. 2009;22:299–306.CrossRefPubMed Niska R, Han B. Anticoagulation for patients with atrial fibrillation in ambulatory care settings. J Am Board Fam Med. 2009;22:299–306.CrossRefPubMed
22.
go back to reference Goren A, Liu X, Gupta S, Simon TA, Phatak H. Warfarin and aspirin use for stroke prevention among patients with atrial fibrillation: the US national health and wellness survey. Am J Ther. 2015;22(4):248–56. Goren A, Liu X, Gupta S, Simon TA, Phatak H. Warfarin and aspirin use for stroke prevention among patients with atrial fibrillation: the US national health and wellness survey. Am J Ther. 2015;22(4):248–56.
23.
go back to reference Stafford RS, Singer DE. National patterns of warfarin use in Atrial Fibrillation. Arch Intern Med. 1996;156:2537–41.CrossRefPubMed Stafford RS, Singer DE. National patterns of warfarin use in Atrial Fibrillation. Arch Intern Med. 1996;156:2537–41.CrossRefPubMed
24.
go back to reference Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:546S–92.CrossRefPubMed Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:546S–92.CrossRefPubMed
26.
go back to reference Zimetbaum PJ. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med. 2010;123:446–53.CrossRefPubMed Zimetbaum PJ. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med. 2010;123:446–53.CrossRefPubMed
27.
go back to reference Schulman S, Beyth RJ. Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. Eur Heart J Suppl. 2005;7:C34–40.CrossRef Schulman S, Beyth RJ. Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. Eur Heart J Suppl. 2005;7:C34–40.CrossRef
28.
go back to reference Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ. 2001;323:1218–22.CrossRefPubMedPubMedCentral Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ. 2001;323:1218–22.CrossRefPubMedPubMedCentral
30.
go back to reference Lewis WR, Fonarow GC, LaBresh KA, Cannon CP, Pan W, Super DM, Sorof SA, Schwamm LH. Differential use of warfarin for secondary stroke prevention in patients with various types of atrial fibrillation. Am J Cardiol. 2009;103:227–31.CrossRefPubMed Lewis WR, Fonarow GC, LaBresh KA, Cannon CP, Pan W, Super DM, Sorof SA, Schwamm LH. Differential use of warfarin for secondary stroke prevention in patients with various types of atrial fibrillation. Am J Cardiol. 2009;103:227–31.CrossRefPubMed
31.
go back to reference Carlsson AC, Wändell P, Sundquist K, Johansson SE, Sundquist J. Peceived Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors’ adherence to warfarin therapy recommendations. Eur J Clin Pharmacol. 2013;69:245–53.CrossRefPubMed Carlsson AC, Wändell P, Sundquist K, Johansson SE, Sundquist J. Peceived Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors’ adherence to warfarin therapy recommendations. Eur J Clin Pharmacol. 2013;69:245–53.CrossRefPubMed
32.
go back to reference Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, Sheldon R, Talajic M, Dorian P, Newman D. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation. 2001;103:2365–70.CrossRefPubMed Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, Sheldon R, Talajic M, Dorian P, Newman D. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation. 2001;103:2365–70.CrossRefPubMed
33.
go back to reference Salas E, Cooke NJ, Rosen RA. On teams, teamwork, and team performance: discoveries and developments. Hum Fact. 2008;50:540.CrossRef Salas E, Cooke NJ, Rosen RA. On teams, teamwork, and team performance: discoveries and developments. Hum Fact. 2008;50:540.CrossRef
34.
go back to reference Salas E, Weaver SJ, DiazGranados D, Lyons R, King H. Sounding the call for team training in health care: some insights and warnings. Acad Med. 2009;84:S128–31.CrossRefPubMed Salas E, Weaver SJ, DiazGranados D, Lyons R, King H. Sounding the call for team training in health care: some insights and warnings. Acad Med. 2009;84:S128–31.CrossRefPubMed
35.
go back to reference Weaver SJ, Lyons R, DiazGranados D, Rosen MA, Salas E, Oglesby J, Augenstein JS, Birnbach DJ, Robinson D, King HB. The anatomy of health care team training and the state of practice: a critical review. Acad Med. 2010;85:1746–60.CrossRefPubMed Weaver SJ, Lyons R, DiazGranados D, Rosen MA, Salas E, Oglesby J, Augenstein JS, Birnbach DJ, Robinson D, King HB. The anatomy of health care team training and the state of practice: a critical review. Acad Med. 2010;85:1746–60.CrossRefPubMed
36.
go back to reference Weaver SJ, Dy SM, Rosen MA. Team-training in healthcare: a narrative synthesis of the literature. BMJ Qual Saf. 2014;0:1–14. Weaver SJ, Dy SM, Rosen MA. Team-training in healthcare: a narrative synthesis of the literature. BMJ Qual Saf. 2014;0:1–14.
37.
go back to reference Grumbach K, Bodenheimer T. Can Health Care Teams Improve Primary Care Practice? JAMA. 2004;291(10):1246–51.CrossRefPubMed Grumbach K, Bodenheimer T. Can Health Care Teams Improve Primary Care Practice? JAMA. 2004;291(10):1246–51.CrossRefPubMed
38.
go back to reference Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998;32:636–41.CrossRefPubMed Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998;32:636–41.CrossRefPubMed
39.
go back to reference Berwick DM, Nolan TW, Whittington J. The triple aim: Care, health, and cost. Health Aff. 2008;27:759–69.CrossRef Berwick DM, Nolan TW, Whittington J. The triple aim: Care, health, and cost. Health Aff. 2008;27:759–69.CrossRef
40.
go back to reference Simpson SH, Lier DA, Majumdar SR, Tsuyuki RT, Lewanczuk RZ, Spooner R, Johnson JA. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial. Diabet Med. 2015; 00, 000–000. Simpson SH, Lier DA, Majumdar SR, Tsuyuki RT, Lewanczuk RZ, Spooner R, Johnson JA. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial. Diabet Med. 2015; 00, 000–000.
Metadata
Title
Adherence to treatment guidelines: the association between stroke risk stratified comparing CHADS2 and CHA2DS2-VASc score levels and warfarin prescription for adult patients with atrial fibrillation
Authors
Scott A. Chapman
Catherine A. St Hill
Meg M. Little
Michael T. Swanoski
Shellina R. Scheiner
Kenric B. Ware
M. Nawal Lutfiyya
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2017
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-017-2025-6

Other articles of this Issue 1/2017

BMC Health Services Research 1/2017 Go to the issue